Canterbury DHB
Choice of treatment of chronic myeloid leukaemia in accelerated and blast crisis should be made by the treating specialist in light of:
Treatment within a clinical trial is preferable.
For previously untreated patients, the 2013 European LeukemiaNet guidelines5 recommend:
Consider alloSCT for fit patients with a high risk for transformation, since the outcome of alloSCT after transformation is unfavourable. Also consider alloSCT early in patients developing AP on a TKI, or high-risk patients with insufficient treatment response.
The only curative option for patients in BP disease is alloSCT. However, for patients considered high risk alloSCT candidates, on-going drug treatment or best supportive care might be the better option.
Topic Code: 533105